NxStage Medical, Inc. (NASDAQ:NXTM) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,724,391 shares, a growth of 53.3% from the November 30th total of 1,777,282 shares. Based on an average trading volume of 682,466 shares, the days-to-cover ratio is presently 4.0 days. Approximately 4.2% of the company’s shares are sold short.
Shares of NxStage Medical (NASDAQ:NXTM) opened at $24.67 on Friday. The company has a market cap of $1,630.00, a P/E ratio of -117.48 and a beta of -0.08. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80.
Several research firms have weighed in on NXTM. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Tuesday, October 17th. Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Northland Securities reiterated a “hold” rating and issued a $30.00 price objective on shares of NxStage Medical in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. NxStage Medical currently has a consensus rating of “Hold” and a consensus target price of $30.25.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 10,500 shares of company stock worth $275,030 in the last 90 days. 4.70% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of NXTM. Athos Capital Ltd bought a new stake in NxStage Medical in the 3rd quarter valued at $579,000. Sterling Capital Management LLC boosted its holdings in NxStage Medical by 26.6% in the 3rd quarter. Sterling Capital Management LLC now owns 81,767 shares of the medical device company’s stock valued at $2,257,000 after purchasing an additional 17,193 shares during the period. California Public Employees Retirement System boosted its holdings in NxStage Medical by 11.7% in the 3rd quarter. California Public Employees Retirement System now owns 103,761 shares of the medical device company’s stock valued at $2,864,000 after purchasing an additional 10,861 shares during the period. Highbridge Capital Management LLC bought a new stake in NxStage Medical in the 3rd quarter valued at $4,140,000. Finally, Burren Capital Advisors Ltd bought a new stake in NxStage Medical in the 3rd quarter valued at $806,000. 85.35% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “NxStage Medical, Inc. (NASDAQ:NXTM) Short Interest Update” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/nxstage-medical-inc-nxtm-sees-significant-increase-in-short-interest.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.